|
Jun 20
|
Gene Therapy Stocks Fall Amid More Turmoil at FDA
|
|
Jun 20
|
Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.
|
|
Jun 20
|
2 Growth Stocks with All-Star Potential and 1 to Ignore
|
|
Jun 19
|
SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls
|
|
Jun 18
|
Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls
|
|
Jun 17
|
Sarepta Therapeutics (NasdaqGS:SRPT) SRP-9003 Gene Therapy Earns FDA Platform Technology Designation
|
|
Jun 17
|
Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
|
|
Jun 17
|
Company News for Jun 17, 2025
|
|
Jun 17
|
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
|
|
May 21
|
Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne
|
|
May 21
|
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
|
|
May 20
|
High Growth Tech Stocks In The US Market To Watch
|
|
May 20
|
3 Stocks Investors May Be Undervaluing By Up To 43.5%
|
|
May 19
|
SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays
|
|
May 19
|
Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy
|
|
May 15
|
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore
|
|
May 14
|
Bearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimates
|
|
May 14
|
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses
|
|
May 13
|
Sarepta Therapeutics Says Duchenne Muscular Dystrophy Treatment Gets Approval in Japan
|
|
May 13
|
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
|